We've rebranded!
HT-ADME is now NE-ADME (New Era of ADME & Beyond) 2022 Conference!
Please visit us at:
https://www.bostonsociety.org/NE-ADME/
HT-ADME 2021 Agenda
*Speakers and titles are subject to change. Updated 6/10/2021
*TIME SLOTS LISTED BELOW ARE EDT!!!
|
Tuesday, June 22, 2021 |
|||
|
Session |
Speaker |
Company |
Time EDT |
|
Conference Opening & Plenary Speaker Introduction |
Maria Fitzgerald | Sanofi |
10:00 - 10:05 |
|
Plenary Lecture Liquid Biopsy in ADME: Where are We Now and Where are We Going? |
David Rodrigues |
Pfizer |
10:05 - 10:45 |
| Q&A |
10:45 - 10:55 |
||
|
SESSION I: Impact of Free Fraction in ADME |
|||
| Session Intro:
Ruchia Duggal, Merck & Chris Rowbottom, Moderna
|
10:55 - 11:00 |
||
| Improved IVIVE for Hepatic Clearance Prediction: The Impact of Albumin on Hepatic Uptake |
Na Li |
C4 Therapeutics |
11:00 - 11:30 |
| Q&A |
11:30 - 11:40 |
||
| Unbound Volume of Distribution as a Foundational Parameter in Drug Design |
Randy Miller & Iain Martin |
Merck Relay Therapeutics |
11:40 - 12:25 |
| Q&A |
12:25 - 12:35 |
||
| Lunch Break & Sponsor Showcase |
12:35 - 1:25 |
||
| Speaker Intro: Chris Rowbottom, Moderna |
1:25:1:30 |
||
| High Throughput Physical Chemistry Assays: Advances and Application | Mark Wenlock |  |
1:30 - 1:55 |
| Q&A |
1:55 - 2:00 |
||
|
SESSION II: In Silico ADME |
|||
|
Session Introduction |
John Janiszewski, NIH & Wilson Shou, BMS
|
2:00 - 2:05 |
|
| NCATS ADME Datasets and In Silico Models Derived from these Datasets |
Xin Xu |
NIH |
2:05 - 2:35 |
| Q&A |
2:35 - 2:45 |
||
| Speaker Intro: | 2:45 - 2:50 | ||
| Mechanistic Insights Into the Inhibitor Preincubation Effect |
Peter Tatrai |
|
2:50 - 3:15 |
| Q&A | 3:15- 3:20 | ||
| HT-ADME: From Data to Knowledge. Generate Data to Feed AI Model Generation and Reach Optimal Compound Design | Ismael Zamora |  |
3:20 - 3:40 |
| Q&A |
3:40 - 3:45 |
||
| Plenary Speaker Intro | John Janiszewski, NIH |
3:45 - 3:50 |
|
|
Plenary Lecture Influencing Design with in silico ADME Models |
Marcel Hop |
Genentech |
3:50 - 4:30 |
|
Q&A |
4:30 - 4:40 | ||
|
Wednesday, June 23, 2021 |
|||
|
SESSION III: ADME for New Modalities |
|||
|
Session Introduction |
|
|
10:00 - 10:05 |
| AAV Gene Therapies - new opportunities for ADME Scientists |
Mark Milton |
Novartis |
10:05 - 10:35 |
| Q&A |
10:35 - 10:45 |
||
| Quantitative and Qualitative Aspects of PROTAC Metabolism: Do they differ from small molecule? |
Beth Williamson |
AstraZeneca, UK |
10:45 -11:15 |
| Q&A |
|
|
11:15 - 11:25 |
| 999Elite™ Cryopreserved Human Hepatocytes |
Albert Li |
|
11:25 - 11:50 |
| Q&A |
11:50- 11:55 |
||
| Lunch Break & Sponsor Showcase |
11:55 - 1:00 |
||
|
SESSION IV: Drug Accumulation/Transporters |
|||
|
Session Introduction |
Mitesh Patel | Novartis |
1:00 - 1:05 |
| The Impact of Ion Trapping on the Cellular Accumulation of Highly Permeable Low Molecular Weight Acidic Drugs |
Dallas Bednarczyk |
Novartis |
1:05 - 1:35 |
| Q&A |
1:35 - 1:45 |
||
| Validation of PXB Chimeric Mice with Humanized Liver to Predict Human Liver-to-Plasma Kpuu of OATP1B1 Substrates | Bo Feng | Vertex |
1:45 - 2:15 |
| Q&A |
2:15 - 2:25 |
||
| Drug Interaction Mediated by Transporter Induction: Current Status and Perspective | Xinning Yang | FDA | 2:25 - 2:55 |
| Q&A | 2:55 - 3:05 | ||
| Importance of Polarized Models for the Evaluation of Hepatic Transporter Based Drug Interactions | Kenneth R. Brouwer |  |
3:05 - 3:15 |
| Q&A |
3:15 - 3:20 |
||
|
SESSION V: COVID and ADME |
|||
|
Session Introduction |
Maria Fitzgerald, Sanofi & Steven Louie, Novartis |
3:20 - 3:25 |
|
|
Plenary Lecture High Throughput Screening and Real World Biomarkers to Predict Drug-Drug and Drug-Nutrient Interactions: Implications to polypharmacy associated with COVID |
Kathy Giacomini | UCSF |
3:25 - 4:05 |
|
Plenary Lecture ADME data on Remdesivir/Treatment Efficacy |
Yurong Lai | Gilead |
4:05 - 4:45 |
|
Panel Discussion Plenary Speakers |
4:45 - 5:00 |
||
| Closing Remarks | 5:00 - 5:05 | ||
